A review of albumin binding in CKD

被引：105

作者：

Meijers, Bjoern K. I. ^{[1
]}

Bammens, Bert ^{[1
]}

Verbeke, Kristin ^{[2
]}

Evenepoel, Pieter ^{[1
]}

机构：

[1] Univ Hosp Leuven, Dept Med, Div Nephrol, Louvain, Belgium

[2] Univ Hosp Leuven, Dept Gastrointest Res, Louvain, Belgium

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2008年 / 51卷 / 05期

关键词：

albumin; albumin binding; protein binding; chronic kidney disease; review;

D O I：

10.1053/j.ajkd.2007.12.035

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Hypoalbuminemia is associated with excess mortality in patients with kidney disease. Albumin is an important oxidant scavenger and an abundant carrier protein for numerous endogenous and exogenous compounds. Several specific binding sites for anionic, neutral, and cationic ligands were described. Overall, the extent of binding depends on the ligand and albumin concentration, albumin-binding affinity, and presence of competing ligands. Chronic kidney disease affects all these determinants. This may result in altered pharmacokinetics and increased risk of toxicity. Renal clearance of albumin-bound solutes mainly depends on tubular clearance. Dialytic clearance by means of conventional hemodialysis/hemofiltration and peritoneal dialysis is limited. Other epuration techniques combining hemodialysis with adsorption have been developed. However, the benefit of these techniques remains to be proved.

引用

页码：839 / 850

页数：12

共 86 条

[11] Biochemical and clinical evidence for uremic toxicity [J].

Bouré, T ;

Vanholder, R .

ARTIFICIAL ORGANS, 2004, 28 (03) :248-253

[12] THE ADSORPTIVE CAPACITY OF SERUM PROTEINS IN RENAL INSUFFICIENCY [J].

BREYER, B ;

RADCLIFF, FJ .

AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1954, 32 (03) :411-419

[13] P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro [J].

Cerini, C ;

Dou, L ;

Anfosso, F ;

Sabatier, F ;

Moal, S ;

Glorieux, G ;

De Smet, R ;

Vanholder, R ;

Dignat-George, F ;

Sampol, J ;

Berland, Y ;

Brunet, P .

THROMBOSIS AND HAEMOSTASIS, 2004, 92 (01) :140-150

[14] Intervention strategies to prevent pathogenetic effects of glycated albumin [J].

Cohen, MP .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) :25-30

[15] Clinical utility of free drug monitoring [J].

Dasgupta, A .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (10) :986-993

[16] Diminished protein binding capacity of uremic sera for valproate following hemodialysis: Role of free fatty acids and uremic compounds [J].

Dasgupta, A ;

Jacques, M ;

Malhotra, D .

AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (04) :327-333

[17] INCREASED FREE PHENYTOIN CONCENTRATIONS IN PREDIALYSIS SERUM COMPARED TO POSTDIALYSIS SERUM IN PATIENTS WITH UREMIA TREATED WITH HEMODIALYSIS - ROLE OF UREMIC COMPOUNDS [J].

DASGUPTA, A ;

ABUALFA, A .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (01) :19-25

[18] Choosing the right nonsteroidal anti-inflammatory drug for the right patient - A pharmacokinetic approach [J].

Davies, NM ;

Skjodt, NM .

CLINICAL PHARMACOKINETICS, 2000, 38 (05) :377-392

[19] Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum [J].

de Loor, H ;

Bammens, B ;

Evenepoel, P ;

De Preter, V ;

Verbeke, K .

CLINICAL CHEMISTRY, 2005, 51 (08) :1535-1538

[20] ALBUMIN BINDING IN UREMIA - QUANTITATIVE ASSESSMENT OF INHIBITION BY ENDOGENOUS LIGANDS AND CARBAMYLATION OF ALBUMIN [J].

DENGLER, TJ ;

ROBERTZVAUPEL, GM ;

DENGLER, HJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (05) :491-499

← 1 2 3 4 5 6 7 8 9 →